IV cefuroxime plus oral clarithromycin or IV erythromycin for the treatment of community-acquired pneumonia in hospitalised patients. A pilot study

Clinical Drug Investigation

Volumn 14, Issue 1, 1997, Pages 23-34

  Gotfried, Mark H ^a,b,c   Killian, Aaron D ^b   Servi, Ronald J ^c   Danziger, Larry H ^b   Rodvold, Keith A ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Pulmonary Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HOSPITAL INFECTION; HOT FLUSH; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREMOR; VERTIGO; VISUAL DISORDER; X RAY ANALYSIS;

EID: 0030877033     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714010-00004     Document Type: Article

References (36)

1. Bates JH, Campbell GD, Barron AL, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest 1992; 101: 1005-12
2. American Thoracic Society. Medical section of the American Lung Association. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26
3. Bowler WA, Hostettler C, Samuelson D, et al. Gastrointestinal side effects of intravenous erythromycin: incidence and reduction with prolonged infusion time and glycopyrrolate pretreatment. Am J Med 1992; 92: 249-53
4. Swanson DJ, Sung RJ, Fine MJ, et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992; 92: 61-8
5. Haefeli WE, Schoenenberger RA, Weiss P, et al. Possible risk for cardiac arrhythmias related to intravenous erythromycin. Int Care Med 1992; 18: 469-73
6. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 Suppl. A: 73-82
7. Neu HC. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother 1991; 27 Suppl. A: 73-82
8. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991; 91 Suppl. 3A: 40-5
9. Guay DR, Patterson DR, Siepman N, et al. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf 1993; 8: 350-64
10. Schonwald S, Gunjaca M, Kolacny-Babic L, et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 1990; 25 Suppl. A: 123-6
11. Barry AL, Jones RN, Thornsberry C. In vitro activities of azithromycin (CP-62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother 1988; 32: 752-4
12. Hardy DJ, Hensey DM, Beyer JM, et al. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988; 32: 1710-9
13. Fernandes PB, Hardy DJ, McDaniel D, et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989; 33: 1531-4
14. Rodvold KA, Gotfried MH, Danziger LH, et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41; 1399-402
15. Fitzgeorge RB, Lever S, Baskerville A. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease. J Antimicrob Chemother 1993; 31 Suppl. E: 171-6
16. Retseema JA, Bergeron JM, Gerard D, et al. Preferential concentration of azithromycin in an infected mouse thigh model. J Antimicrob Chemother 1993; 31 Suppl. E: 5-16
17. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
19. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991; 115: 428-36
20. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial disk susceptibility tests. 5th ed. Villanova, Pennsylvania: The Committee, 1993
21. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Villanova, Pennsylvania: The Committee, 1993
22. Garrett HM, editor. Red book 1996 Montvale, New Jersey. Medical Economics Data 1996
23. Schentag JJ, Vari AJ, Winslade NE, et al. Treatment of aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med 1985; 78 Suppl 2A: 34-41
24. Chien S-M, Pichotta P, Siepman N, et al. Treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Chest 1993; 103: 697-701
25. Anderson G, Esmonde TS, Coles S, et al. A comparative safely and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother 1991; 27 Suppl. A: 117-24
26. Straneo G, Scarpazza G. Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. J Int Med Res 1990; 18: 164-70
27. Poirier R. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1991; 27 Suppl. A: 109-16
28. Fang G-D, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69: 307-16
29. Mittl RL, Schwab RJ, Duchin JS, et al. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994; 149: 630-5
30. Evans WE, Schentag JJ, Jusko WJ, editors. Chapter 2: Guidelines for collection and analysis of pharmacokinetic data. In Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver. Applied Therapeutics, Inc. 1992
31. Plouffe JF, Herbert MT, File TM Jr, et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalisation. Pneumonia Study Group. Antimicrob Agents Chemother 1996; 40: 1175-9
32. Dabernat H, Delmas C, Seguy M, et al. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests. J Antimicrob Chemother 1991; 21 Suppl. A: 19-30
33. Hardy DJ, Swanson RN, Rode RA, et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990; 34: 1407-13
34. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91: 462-70
35. Gentry LO, Rodriguez-Gomez G, Kohler RB, et al. Parenteral followed by oral ofloxacin for nosocomial and community-acquired pneumonia requiring hospitalization. Am Rev Respir Dis 1992; 145: 31-5
36. Ramirez, JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-6